ibrutinib,zanubrutinib
abbvie,beigene,janssen
['leukemia', 'zanubrutinib', ' ibru']
a 2nd-generation drug, zanubrutinib, is about to unseat ibrutinib as the king on the block for chronic lymphocytic leukemia treatment, said catherine diefenbach, from 's . "this is sort of the end of ibrutinib." 
Veteran health communicator: Dir Cancer Comm - Perlmutter Cancer Ctr @nyulangone Health. Past comm leader @ JAMA, Duke, Emory, AAP, AACR. Tweets are my own.